IL2 and cancer: The treatment of AZD5363 on its own did not induce significant cancer cell death or led to brighter fluorescence labeling by the compound H5, whereas the same concentration of AZD5363 in combination with 100 U mL−1 IL-2 caused significant cancer cell death and H5 fluorescence emission in CD8+ T cell-E0771 cell co-cultures (Fig. S16).